This Week in Biotech: AbbVie Inc (ABBV) and More

Late in the week, Amicus did its best to mix the positives with the negatives, but investors failed to see it that way. On Thursday, Amicus announced positive clinical and pre-clinical data of AT2220, its co-administered pharmacological chaperone given with enzyme replacement therapy for the treatment of Pompe disease. However, Amicus spoiled that optimism just 24 hours later by reporting additional late-stage data from its Fabry monotherapy study. Management called the data “encouraging”; however, just as we saw when Amicus imploded in December, there wasn’t enough statistical difference between migalastat HCl and the control arm to label it as significant. Investors pounced on the stock following this release and sent shares down nearly 26% on Friday.

The article This Week in Biotech originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool recommends and owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.